Back to Search
Start Over
Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges
- Source :
- Life Sciences
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- The recent outbreak of Coronavirus disease (COVID-19), first in Eastern Asia and then essentially across the world has been declared a pandemic by the WHO. COVID-19 is caused by a novel virus SARS-CoV2 (2019-nCoV), against which there is currently no vaccine available; and current antiviral therapies have failed, causing a very high mortality rate. Drug repurposing i.e. utilizing an approved drug for different indication, offers a time- and cost-efficient alternative for making new therapies available to patients. Although there are several reports presenting novel approaches to treat COVID-19, still an attentive review of previous scientific literature is essential to overcome their failure to exhibit efficacy. There is an urgent need to provide a comprehensive outlook toward utilizing drug repurposing as a tool for discovery of new therapies against COVID-19. In this article, we aim to provide a to-the-point review of current literature regarding efficacy of repurposed drugs against COVID-19 and other respiratory infections caused by coronaviruses. We have briefly discussed COVID-19 epidemiology, and then have discussed drug repurposing approaches and examples, specific to respiratory viruses. Limitations of utilization of repurposed drug molecules such as dosage regimen and associated challenges such as localized delivery in respiratory tract have also been discussed in detail.<br />Graphical abstract Unlabelled Image
- Subjects :
- 0301 basic medicine
Drug
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
media_common.quotation_subject
Pneumonia, Viral
Drug repurposing
Disease
Molecular Dynamics Simulation
medicine.disease_cause
030226 pharmacology & pharmacy
Approved drug
Antiviral Agents
Article
General Biochemistry, Genetics and Molecular Biology
03 medical and health sciences
Betacoronavirus
0302 clinical medicine
Pandemic
medicine
Humans
General Pharmacology, Toxicology and Pharmaceutics
Intensive care medicine
Pandemics
Coronavirus
media_common
Localized delivery
business.industry
SARS-CoV-2
Drug Repositioning
COVID-19
General Medicine
FDA approved drugs
Molecular Docking Simulation
Drug repositioning
Regimen
030104 developmental biology
SARS-CoV2
business
Coronavirus Infections
Subjects
Details
- Language :
- English
- ISSN :
- 00243205
- Database :
- OpenAIRE
- Journal :
- Life Sciences
- Accession number :
- edsair.doi.dedup.....a3ad8497f6736d0a43014eff725e48c9
- Full Text :
- https://doi.org/10.1016/j.lfs.2020.118275